Welcome and Comments
Cindi Jones, Director

Call to Order
Tim Jennings, Pharm.D, Chair

Drug Utilization Review (DUR) Board Report
Avtar Dhillon, M.D., DMAS DUR Board

Magellan Medicaid Administration Update
Debbie Moody, RPh, Clinical Manager

Approval of Minutes from October 16, 2014 Meeting
P&T Committee Members

PDL Management
P&T Committee Members

- Old Business

- Potential New Therapeutic Class Review (PDL Category)
  - Gastrointestinal (Antibiotic-Anti-Infective)
  - Pancreatic Enzymes (Endocrine and Metabolic Agents)
  - Antifungals: Topical (Dermatologic)
  - Self Injectable Immunomodulators for RA - Potential expansion to include Self Injectable Cytokine and CAM Antagonists and Related Agents for all indications (Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn’s Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS) (Immunological Agents)

- PDL Phase I – New Drug Review (Therapeutic Class)
  - Akynzeo® (Antiemetics/Antivertigo Agents)
  - Amlodipine/valsartan/HCTZ & amlodipine/valsartan (Angiotensin Modulator Combinations)
  - Arinut Ellipta® (Inhaled Corticosteroids)
  - Asmanex® HFA (Inhaled Corticosteroids)
  - Belsomra® (Sedatives/Hypnotics)
  - Children’s Qnasal® (Inhaled Antihistamines)
  - Ferric citrate (Phosphate Binders)
  - Fexofenadine Suspension (Second Generation Antihistamines)
  - Flonase® OTC (Inhaled Antihistamines)
  - Incruse Ellipta™ (COPD)
  - Olopatadine – generic for Pantanase® (Intranasal Antihistamines)
  - Spiriva® Respimat (COPD)
  - Striverdi® Respimat (Long Acting Beta Adrenergic Agents)
  - Tacrolimus – generic for Protopic® (Atopic Dermatitis: Topical)
  - Testosterone – generics for Androgel® and Fortesta® (Androgenic Agents)

- PDL Phase II – Annual Review (Therapeutic Class)
  - Analgesics
  - Barbiturate & Non-salicylate Analgesics (and combinations)
  - Narcotics (includes long acting, short acting, combinations, and lozenges)
  - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (includes Cox-2 inhibitors)
  - Opioid Analgesics & Dependency
  - Topical Agents & Anesthetics
• **PDL Phase II – Annual Review (continued)**
  o **Antibiotics/Anti-infectives**
    - 2nd and 3rd Generation Cephalosporins
    - 2nd and 3rd Generation Quinolones (systemic)
    - Ketolides & Macrolides (adult and pediatric)
    - Oral Antifungals
    - Otic Quinolones
    - Topical Antibiotics
  o **Antivirals**
    - Antivirals for the Treatment of Herpes or Influenza
    - Hepatitis C Agents
    - Topical Antivirals
  o **Bone Resorption Suppression and Related Agents**
    - Bisphosphonates
    - Calcitonins
    - Others
  o **Cardiac Medications**
    - Anticoagulants *(includes low molecular weight heparins, Factor XA inhibitors and oral anticoagulants)*
    - Platelet Inhibitors
  o **Central Nervous System**
    - Antihyperkinesis/CNS Stimulants
    - Antimigraine
    - Non-Ergot Dopamine Receptor Agonists
    - Skeletal Muscle Relaxants
    - Smoking Cessation
  o **Dermatologic**
    - Acne Agents *(includes benzoyl peroxide, clindamycin, topical retinoids & combinations)*
    - Topical Agents For Psoriasis
  o **Endocrine and Metabolic Agents**
    - Androgenic Agents
    - Antihyperuricemics
    - Contraceptives *(oral, vaginal & transdermal)*
    - Erythropoiosis Stimulating Proteins
    - Injectable Hypoglycemics *(includes insulins, incretin mimetics, GLP-1 receptor agonists)*
    - Oral Hypoglycemics *(includes 2nd generation sulfonylureas, alpha-glucosidase inhibitors, biguanides, biguanide combinations, meglitinides, thiazolidinediones, DPP-IV inhibitors and combinations Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor)*
    - Progestational Agents
    - Vaginal Estrogens
  o **Immunologic Agents**
    - Multiple Sclerosis Agents
    - Self Administered Drugs for Rheumatoid Arthritis

**Confidential Meeting (Pricing Information Discussion)**
P&T Committee Members & DMAS Staff

**Criteria Discussion of Phase I New Drugs**
P&T Committee Members

**Criteria Discussion of Phase II Drugs**
P&T Committee Members

**Next Meeting – October 15, 2015 (tentative)**
Chair
Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on only the drug classes in Phase II which are scheduled for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – April 2014 to present
- New Drugs in PDL Phase I Drug Classes – April 2013 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Thursday, March 26, 2015.